Tags

Type your tag names separated by a space and hit enter

The dual actions of Sanmiao wan as a hypouricemic agent: down-regulation of hepatic XOD and renal mURAT1 in hyperuricemic mice.
J Ethnopharmacol. 2010 Mar 02; 128(1):107-15.JE

Abstract

ETHNOPHARMACOLOGICAL RELEVANCE

Sanmiao wan (SMW) is widely used for the treatment of gout and hyperuricemia in traditional Chinese medicine.

AIM OF THE STUDY

The aim of the present study was to investigate the hypouricemic effects of SMW and its possible mechanism in potassium oxonate-induced hyperuricemic mice.

MATERIALS AND METHODS

SMW at 489, 978 and 1956 mg/kg was orally administered to hyperuricemic and normal mice, and standard drug allopurinol (2.5mg/kg) was served as a positive control. The effects of SMW on serum, urine and liver levels of uric acid, serum levels of creatinine, and activity of hepatic xanthine oxidase (XOD) were measured in mice. Moreover, the effects of SMW on the mRNA and protein levels of hepatic XOD and renal urate transporter 1 (mURAT1) in mice were analyzed by semi-quantitative RT-PCR and Western blotting methods, respectively.

RESULTS

SMW significantly reduced uric acid levels in serum and liver, inhibited hepatic XOD activity, mRNA and protein levels in hyperuricemic mice. Furthermore, SMW could effectively down-regulate renal mURAT1 mRNA and protein levels of hyperuricemic mice. And it reversed oxonate-induced elevation in serum creatinine levels of mice. However, SMW did not show any effects in normal mice.

CONCLUSION

These findings suggested that SMW produced dual hypouricemic actions by suppressing hepatic XOD to reduce uric acid production and down-regulating renal mURAT1 to decrease urate reabsorption and enhance urate excretion in hyperuricemic mice.

Authors+Show Affiliations

State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Han kou Road 22, Nanjing 210093, PR China.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

20051260

Citation

Wang, Xing, et al. "The Dual Actions of Sanmiao Wan as a Hypouricemic Agent: Down-regulation of Hepatic XOD and Renal mURAT1 in Hyperuricemic Mice." Journal of Ethnopharmacology, vol. 128, no. 1, 2010, pp. 107-15.
Wang X, Wang CP, Hu QH, et al. The dual actions of Sanmiao wan as a hypouricemic agent: down-regulation of hepatic XOD and renal mURAT1 in hyperuricemic mice. J Ethnopharmacol. 2010;128(1):107-15.
Wang, X., Wang, C. P., Hu, Q. H., Lv, Y. Z., Zhang, X., Ouyang, Z., & Kong, L. D. (2010). The dual actions of Sanmiao wan as a hypouricemic agent: down-regulation of hepatic XOD and renal mURAT1 in hyperuricemic mice. Journal of Ethnopharmacology, 128(1), 107-15. https://doi.org/10.1016/j.jep.2009.12.035
Wang X, et al. The Dual Actions of Sanmiao Wan as a Hypouricemic Agent: Down-regulation of Hepatic XOD and Renal mURAT1 in Hyperuricemic Mice. J Ethnopharmacol. 2010 Mar 2;128(1):107-15. PubMed PMID: 20051260.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The dual actions of Sanmiao wan as a hypouricemic agent: down-regulation of hepatic XOD and renal mURAT1 in hyperuricemic mice. AU - Wang,Xing, AU - Wang,Cai-Ping, AU - Hu,Qing-Hua, AU - Lv,Yao-Zhong, AU - Zhang,Xian, AU - Ouyang,Zhen, AU - Kong,Ling-Dong, Y1 - 2010/01/04/ PY - 2009/05/21/received PY - 2009/09/27/revised PY - 2009/12/28/accepted PY - 2010/1/7/entrez PY - 2010/1/7/pubmed PY - 2010/6/19/medline SP - 107 EP - 15 JF - Journal of ethnopharmacology JO - J Ethnopharmacol VL - 128 IS - 1 N2 - ETHNOPHARMACOLOGICAL RELEVANCE: Sanmiao wan (SMW) is widely used for the treatment of gout and hyperuricemia in traditional Chinese medicine. AIM OF THE STUDY: The aim of the present study was to investigate the hypouricemic effects of SMW and its possible mechanism in potassium oxonate-induced hyperuricemic mice. MATERIALS AND METHODS: SMW at 489, 978 and 1956 mg/kg was orally administered to hyperuricemic and normal mice, and standard drug allopurinol (2.5mg/kg) was served as a positive control. The effects of SMW on serum, urine and liver levels of uric acid, serum levels of creatinine, and activity of hepatic xanthine oxidase (XOD) were measured in mice. Moreover, the effects of SMW on the mRNA and protein levels of hepatic XOD and renal urate transporter 1 (mURAT1) in mice were analyzed by semi-quantitative RT-PCR and Western blotting methods, respectively. RESULTS: SMW significantly reduced uric acid levels in serum and liver, inhibited hepatic XOD activity, mRNA and protein levels in hyperuricemic mice. Furthermore, SMW could effectively down-regulate renal mURAT1 mRNA and protein levels of hyperuricemic mice. And it reversed oxonate-induced elevation in serum creatinine levels of mice. However, SMW did not show any effects in normal mice. CONCLUSION: These findings suggested that SMW produced dual hypouricemic actions by suppressing hepatic XOD to reduce uric acid production and down-regulating renal mURAT1 to decrease urate reabsorption and enhance urate excretion in hyperuricemic mice. SN - 1872-7573 UR - https://www.unboundmedicine.com/medline/citation/20051260/The_dual_actions_of_Sanmiao_wan_as_a_hypouricemic_agent:_down_regulation_of_hepatic_XOD_and_renal_mURAT1_in_hyperuricemic_mice_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0378-8741(09)00790-9 DB - PRIME DP - Unbound Medicine ER -